Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
- HIV / AIDs
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 5352
o U.S. Patent No. 5,128,319 entitled 'Prophylaxis and Therapy of Acquired Immunodeficiency Syndrome', (MDA REF UTSC234)
o MDA REF UTSC242 entitled 'Methods and Compositions for the Priming of Specific Cytotoxic T-Lymphocyte Response'
o MDA REF UTSC267 (Divisional of UTSC234) 'Prophylaxis and Therapy of Acquired Immunodeficiency Syndrome'
o MDA REF UTSC305 entitled 'Compositions and Methods for Eliciting Immune or Anti-Infective Responses'
o MDA REF UTSC331 entitled 'CD4 Peptides for Binding to Viral Envelope Proteins'
o MDA REF UTSC381 entitled 'Peptides for Inhibitiing the Infection of Target Cells by Lentiviruses'
IPSCIO Record ID: 26363
The patents covering a peptide product, known as BlockAide, for the treatment and prevention of HIV.
IPSCIO Record ID: 203504
IPSCIO Record ID: 27353
U.S. Patent No. 5,460,830 entitled 'Biochemically Active Agents for Chemical Catalysis and Cell Receptor Activation', U.S. Patent No. 5,460,831 entitled 'Targeted Transfection Nanoparticles', U.S. Patent No. 5,462,750 entitled 'Biologically Active Compositions Having a Nanocrystalline Core', U.S. Patent No. 5,462,751 entitled 'Biological and Pharmaceutical Agents Having a Nanomeric Biodegradable Core' and U.S. Patent No. 5,464,634 entitled 'Red Blood Cell Surrogate'.